[go: up one dir, main page]

NO995257L - Fremgangsmåte og materialer for diagnose og behandling av Reward Deficiency Syndrome - Google Patents

Fremgangsmåte og materialer for diagnose og behandling av Reward Deficiency Syndrome

Info

Publication number
NO995257L
NO995257L NO995257A NO995257A NO995257L NO 995257 L NO995257 L NO 995257L NO 995257 A NO995257 A NO 995257A NO 995257 A NO995257 A NO 995257A NO 995257 L NO995257 L NO 995257L
Authority
NO
Norway
Prior art keywords
inhibitor
precursor
phenylalanine
dopamine
enkephalinase
Prior art date
Application number
NO995257A
Other languages
English (en)
Norwegian (no)
Other versions
NO995257D0 (no
Inventor
Kenneth Blum
David E Comings
John L Ivy
Original Assignee
Kenneth Blum Inc
Univ Texas
Hope Nat Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Blum Inc, Univ Texas, Hope Nat Medical Center filed Critical Kenneth Blum Inc
Publication of NO995257D0 publication Critical patent/NO995257D0/no
Publication of NO995257L publication Critical patent/NO995257L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
NO995257A 1997-04-29 1999-10-28 Fremgangsmåte og materialer for diagnose og behandling av Reward Deficiency Syndrome NO995257L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4439497P 1997-04-29 1997-04-29
PCT/US1998/008684 WO1998048785A2 (fr) 1997-04-29 1998-04-29 Diagnostic d'un syndrome d'insatisfaction a l'aide de polygene allelique et traitement associe

Publications (2)

Publication Number Publication Date
NO995257D0 NO995257D0 (no) 1999-10-28
NO995257L true NO995257L (no) 1999-12-27

Family

ID=21932148

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995257A NO995257L (no) 1997-04-29 1999-10-28 Fremgangsmåte og materialer for diagnose og behandling av Reward Deficiency Syndrome

Country Status (10)

Country Link
EP (1) EP0979092A2 (fr)
JP (1) JP2002511850A (fr)
KR (1) KR20010020422A (fr)
CN (1) CN1261801A (fr)
AU (1) AU7267798A (fr)
CA (1) CA2288990A1 (fr)
IL (1) IL132634A0 (fr)
IS (1) IS5233A (fr)
NO (1) NO995257L (fr)
WO (1) WO1998048785A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6132724A (en) * 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US6955873B1 (en) * 2000-08-04 2005-10-18 Kenneth Blum Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors
GB9927806D0 (en) * 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
JP2004525867A (ja) * 2000-12-01 2004-08-26 ビー エイブル エルエルシー 行動化学療法
ITRM20010218A1 (it) * 2001-04-23 2002-10-23 Sigma Tau Healthscience Spa Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
US7713695B2 (en) * 2005-02-07 2010-05-11 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
WO2008038710A1 (fr) 2006-09-28 2008-04-03 Mitsubishi Electric Corporation Détecteur de défauts, procédé et programme de détection de défauts
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
EP2485747A4 (fr) * 2008-06-21 2013-10-23 Kenneth Blum Personnalisation dirigée par l'adn des composés analgesiques comme modalité thérapeutique
WO2010005303A2 (fr) * 2008-07-07 2010-01-14 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Nouveaux indicateurs de longévité humaine et du taux de vieillissement biologique
SG184395A1 (en) 2010-04-01 2012-11-29 Ecole Polytech Device for interacting with neurological tissue and methods of making and using the same
EP2585824A4 (fr) * 2010-04-22 2014-01-01 Kenber Llc Analyse du risque génétique dans le syndrome du déficit de récompense
US9727691B2 (en) 2011-09-30 2017-08-08 Tokyo Metropolitan Institute Of Medical Science Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
JP2015067581A (ja) * 2013-09-30 2015-04-13 国立大学法人京都大学 多重共鳴用のプローブ
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
CN103990106A (zh) * 2014-06-11 2014-08-20 河北医科大学 八肽胆囊收缩素在制药中的应用
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9925376B2 (en) * 2014-08-27 2018-03-27 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
CN104846015B (zh) * 2015-05-27 2018-03-27 深圳先进技术研究院 特异性兴奋伏隔核中的gaba能神经元的组合物及其在改善精神分裂症异样行为中的应用
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
DE102018114364A1 (de) * 2018-06-15 2019-12-19 Susanne Koch Verfahren und Vorrichtungen zur Bereitstellung eines Parameters, der auf eine erhöhte Wahrscheinlichkeit des Auftretens eines postoperativen Delirs hinweist
CN109316196B (zh) * 2018-12-12 2022-07-19 上海市精神卫生中心（上海市心理咨询培训中心） 基于虚拟现实联合脑电监测的苯丙胺类兴奋剂渴求评估方法
CN110507294B (zh) * 2019-08-07 2022-02-08 北京安龙脉德医学科技有限公司 基于互联网信息传递的急救系统
CN110991044B (zh) * 2019-12-03 2023-02-24 北京机电工程研究所 基于Agent建模的飞行器系统任务可靠性评估方法
CN112862751B (zh) * 2020-12-30 2022-05-31 电子科技大学 一种用于自闭症的自动诊断装置
CN113332299A (zh) * 2021-05-27 2021-09-03 广东湛江海洋医药研究院 红景天苷在缓解糖皮质激素性骨质疏松症中的应用
KR102434668B1 (ko) * 2022-03-02 2022-08-22 주식회사 국개대표 분리 불안 증상을 개선할 수 있는 반려동물용 사료 및 그 제조방법
CN115830001B (zh) * 2022-12-22 2023-09-08 抖音视界有限公司 肠道图像处理方法、装置、存储介质及电子设备
CN116310717B (zh) * 2023-02-14 2025-06-20 长沙理工大学 目标学生网络模型训练方法及低分辨率图像识别方法
CN116820166B (zh) * 2023-06-08 2024-07-19 武汉汉联智控科技有限公司 一种高低温控温控流量系统及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4761429A (en) * 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5013752A (en) * 1989-03-10 1991-05-07 Dobbins John P Prevention and treatment of alcoholism by the use of dietary chromium
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity

Also Published As

Publication number Publication date
IL132634A0 (en) 2001-03-19
WO1998048785A9 (fr) 1999-05-20
NO995257D0 (no) 1999-10-28
EP0979092A2 (fr) 2000-02-16
CA2288990A1 (fr) 1998-11-05
AU7267798A (en) 1998-11-24
KR20010020422A (ko) 2001-03-15
WO1998048785A2 (fr) 1998-11-05
JP2002511850A (ja) 2002-04-16
CN1261801A (zh) 2000-08-02
IS5233A (is) 1999-10-28
WO1998048785A3 (fr) 1999-04-01

Similar Documents

Publication Publication Date Title
NO995257L (no) Fremgangsmåte og materialer for diagnose og behandling av Reward Deficiency Syndrome
Walker et al. The γ‐aminobutyric acid‐B receptor agonist baclofen attenuates responding for ethanol in ethanol‐dependent rats
Cuajungco et al. Metal chelation as a potential therapy for Alzheimer's disease
Murray et al. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function
Bidaut-Russell et al. Adverse gastrointestinal effects of NSAIDs: consequences and costs
DK0668851T3 (da) Hidtil ukendt arylpropionsyrederivat, fremgangsmåde til fremstilling heraf og anvendelse heraf som analgetisk middel
WO2008118148A3 (fr) Adiponectine pour le traitement et le diagnostic de l'albuminurie
NO20081847L (no) Fremgangsmate for a forbedre kognitiv funksjon
EP2327451A3 (fr) Procédés de détection et d'inhibition de l'angiogénèse
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
DE60016866D1 (de) Verfahren und vorrichtung zur behandlung von datenverfälschung und gemeinsam genutzte platten im kontext von datensicherung, -benützung und wiederherstellung
Villetti et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea‐pig and human airways
PT883619E (pt) Sais de morfina e de diamorfina de analgesicos anionicos nao-narcoticos do tipo dos acidos carboxilicos substituidos
Krstić et al. Inhibition of Na+/K+-ATPase and Mg2+-ATPase by metal ions and prevention and recovery of inhibited activities by chelators
Lyon Metabolic panniculitis: alpha‐1 antitrypsin deficiency panniculitis and pancreatic panniculitis
Jiang et al. Endothelium‐dependent vasorelaxation independent of nitric oxide and K+ release in isolated renal arteries of rats
Saag et al. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics
Tiitinen et al. Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid
Korpela et al. Oral naproxen but not oral paracetamol reduces the need for rescue analgesic after adenoidectomy in children
Barish et al. " As far as possible": Discovering our limits and finding ourselves
WO2007022059A3 (fr) Inhibition de l'activité phosphatase de l'extrémité amine d'une époxyde hydrolase soluble et applications
Kivirikko et al. Synthesis of collagen: chemical regulation of post-translational events
Petek et al. Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice
Corrigan Jr et al. Treatment of chronic haemophilic synovitis in humans with D‐penicillamine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application